Home » Drug Information » FDA-Approved Drugs » 1997
Medical Areas: Cardiology/Vascular Diseases | Endocrinology
View By: Year Company Therapeutic Areas Drug Names
Drug Information
The following information is obtained from various newswires, published
medical journal articles, and medical conference presentations.
Company: Roche
Approval Status: Approved June 1997
Treatment Area: hypertension and chronic stable angina pectoris
Posicor (mibefradil), a calcium channel blocker, will be
available in 50 mg and 100 mg tablets for treatment of chronic
stable angina pectoris and hypertension. Posicor is approved for
use by itself or in combination with other antihypertensive or
anti-anginal agents.
Posicor is contraindicated for use with astemizole, terfenadine
and cisapride because it is metabolized by the cytochrome P450 2D6
isoenzyme. It can be life-threatening when used in conjunction with
agents metabolized by P450.
Mibefradil, a subtype calcium channel blocker, blocks both low
and high voltage calcium channels with greater selectivity for low
voltage or Type T channels. While decreasing blood pressure,
Posicor doesn’t lessen heart contractions, unlike beta
blockers.
